Small Pharma is developing N,N-dimethyltryptamine (DMT) and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination with psychotherapy as potential rapid onset, sustained treatments for depression and other mental health disorders.We are working closely with experts from this world-leading psychedelic research group as we conduct our first randomised controlled, placebo-controlled Phase I/II...
Small Pharma is developing N,N-dimethyltryptamine (DMT) and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination with psychotherapy as potential rapid onset, sustained treatments for depression and other mental health disorders.We are working closely with experts from this world-leading psychedelic research group as we conduct our first randomised controlled, placebo-controlled Phase I/IIa trial of DMT-assisted therapy in both healthy volunteers and patients in London.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.